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Abstract
Introduction: Sulfur mustard “bis (2-chlroethyl) sulphide” (SM) is a chemical warfare
agent that remains a threat to human health. The aim of this study was to identify
protein expression signature or biomarkers that reflect chronic lung damages
induced by SM exposure.
Methods: Prior to analysis, plasma was fractionated using ethanol precipitation.
Using two dimensional SDS-PAGE; fractionated protein profiles of 20 healthy and 20
exposed patients with lung diseases were established. Selected protein spots were
successfully identified with MALDI TOF MS/MS.
Results: The results show that a1 haptoglobin isoforms were detected in plasma of
the all lung disease patients but none of the healthy controls. Amyloid A1 isoforms
was also detected in plasma of the lung disease patients but none of the healthy
controls. Moreover, low molecular weight proteins were enriched in ethanol
supernatant compared to ethanol precipitate.
Conclusion: Our present results and previous studies suggest that ongoing tissue
remodeling is involved in SM exposed lung damage patients. These finding might
improve patient care and suitable therapies.
Introduction
Sulfur mustard is a chemical warfare agent that remains a threat to human health..
More than lethality, SM causes debilitating effects that can leave an exposed individual
incapacitated for days, months, or years. Lung injury is a common health problem
after inhalation, which leads to chronic bronchitis and interstitial lung diseases [1].
The clinical picture of the poisoning is well known from the thousands of victims dur-
ing World War I and the recent Iran-Iraq conflict. In the latter, sulfur mustard was
heavily used and at the present time about 30,000 victims still suffer from late effects
of the agent, such as chronic obstructive lung disease, lung fibrosis, recurrent corneal
ulcer disease, and chronic conjunctivitis [2]. Late complications of mustard gas expo-
sure and main clinical findings include; chronic bronchitis, bronchiectasis and bronch-
iolitis obliterans (BO) [3-5]. However, Clinical manifestation in lung disorders due to
sulfur mustard is different from other lung diseases, due to the fact that mustard lung
is not responsive to corticosteroids. There is no common consensus about the
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agent [6].
Proteomics technologies can identify and quantify novel proteins in the plasma that
can function as biomarkers of the presence or severity of disease states. In general,
human plasma proteome profiling is challenging. Albumin is present at about 40 mg/
ml and several other proteins are highly abundant including immunoglobulins (IgGs),
transferrin and fibrinogen which typically constitute greater than 90% of total protein
mass [7]. These abundant proteins may hinder the detection of low-abundant proteins
that can be of specific interest in the search for biomarkers of disease [8]. However, it
is the low abundant proteins that are most likely to be biologically relevant as the mar-
kers of a disease state. For analysis of low-abundant proteins in plasma, many strate-
gies have been developed for the selective removal of albumin and other high-
abundance proteins. Albumin can be removed by immune affinity columns chromato-
graphy [9], isoelectric trapping [10], heparin chromatography [11] and peptide affinity
chromatography [12]. However, it is well known that albumin and other high-abun-
dance proteins may also act as carrier or transport proteins and thus are likely to bind
many species of interest, such as peptide hormones, cytokines, and chemokines.
There are wide-ranging interests in using the proteomics approach to define markers
of lung disease. Although respiratory tract lesions represent the major disability after
S Me x p o s u r e ,o n l yaf e ws t u d i e sh a v ei n v e s t i g a t e dt h el o n gt e r mp a t h o p h y s i o l o g yo f
SM induced respiratory damages, in particular their proteomes. We have recently
examined the proteomics pattern in bronchoalveolar lavage (BAL) fluid of SM exposed
patients and identified families of proteins whose expression is up or down regulated
compared to healthy controls [13]. Plasma proteins and peptides are from almost every
tissue and cell, and their change in quantity and quality is specific not only to the tis-
sue affected by disease, but also to the disease process itself. In addition, plasma is the
most easily accessible, less invasive, and widely collected sample.
We attempted to explore plasma proteomics patterns of these patients, using ethanol
fractionation. Tow-dimensional gel electrophoresis was applied and followed by
MALDI-TOF MS to look for new markers in the plasma of exposed patients which
may help in further understanding the nature of long term effects of mustard gas.
These finding might improve patient care and finding suitable therapies.
Results
The plasma protein content of the patients and the controls are presented in Table 1.
No significant differences were observed in plasma protein contents of patients and
controls.
The ethanol fractionation was used to enrich low molecular weight proteins. As
shown in Figure 1, most of the low molecular weight proteins were enriched in the
ethanol supernatant rather than the precipitate. We found that 50% (v/v) ethanol was
more efficient in fractionating low molecular weight proteins. To avoid any protein
Table 1 Age and plasma protein concentrations of patients and control subjects
a
Variables Healthy Controls Severe Patients
Age (year) 40.1 ± 3.6 43.6 ± 2.8
Protein in plasma (mg/ml) 71.6 ± 3.1 72.4 ± 5.3
a. Data are mean ± SEM (n = 20 in each group).
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for 2-DE analysis. For the first dimension 24 cm IPG strips with pH values in the
range of 4-7 were used. The proteins were resolved in homogeneous 15% acrylamide
gels in the second dimension to obtain greater resolution for small proteins. About
300 spots in each colloidal CBB-stained gel can be visualized by ImageMaster software.
Representative 2-DE images of plasma profiles from a healthy control for 50% (v/v)
ethanol precipitate and ethanol supernatant are shown in Figure 2A and 2B respec-
tively. Comparing the proteomics patterns of these two gels shows that both immuno-
globulin heavy and light chains are separated in ethanol precipitate (Figure 2A) and
albumin is distributed both in ethanol supernatant and precipitate (Figure 2A and 2B).
Moreover, most of the small molecular weight proteins in the range of 15-50 kDa,
h a v es i g n i f i c a n t l y( p<0 . 0 5 )h i g h e rs p o tv o l ume and intensity in ethanol supernatant
rather than precipitate (Table 2 and Figures. 2A and 2A).
We analyzed the differences in the plasma protein patterns, comparing the gels of
the diseased and healthy controls. The analysis of protein patterns of the plasma was
focused on those protein spots which showed differences, comparing the patients and
the controls. They were compared with Image Master 2-DE software and indicated
only protein results in all cases (100%) with the same condition. As shown in Figures 2
B and 2C, twenty six protein spots were subjected to MALDI TOF MS analysis. All
selected proteins and their isoforms were subsequently identified by PMF and MS/MS
     U      S25%    P25%   S50%   P50%    S75% P75% 
Figure 1 SDS-PAGE of plasma proteins fractionated with different concentrations (v/v) of ethanol.U
represents plasma proteins before precipitation; S, ethanol supernatant; P, ethanol precipitate. Samples
were analysed as described in the Method section and gels were stained using silver staining.
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Page 3 of 11analysis. Table 3 lists the identities of the proteins and their isoforms which were ana-
lyzed in this experiment using MALDI TOF MS. Figures 2B and 2C shows the location
of these protein spots in the 2-DE gels of a healthy controls and an exposed patients
respectively. Volume and intensity of those protein spots which were only present in
all patients’ plasma but none of the healthy controls are shown in Table 4. Images
from other healthy volunteers and patients were similar (data not shown).
Haptoglobin a1 chain isoforms (spots 21, 22 and 23) were only detected in the
plasma of the severe lung diseases patients but were not detectable in healthy controls
(Figure 2B and 2C). Furthermore, serum Amyloid A1 isoforms (spots 24 and 26) were
only seen in the plasma of the patients but none of the healthy controls (Figure 2B
and 2C).
Discussion
In this study we present plasma proteome analysis of SM exposed patients compared
to the healthy controls. Human plasma and serum represent important biological
materials for disease diagnosis. However, the wide dynamic range in protein concentra-
tions remains a major challenge in the development of diagnostic assays. Human
plasma albumin and the various forms of immunoglobulin represent the most abun-
dant proteins in the plasma, constituting up to 80% of the total plasma proteins. The
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Figure 2 Representative 2-DE protein patterns of plasma from healthy and severe lung diseases
patients exposed to SM. Plasma proteins were fractionated using 50% (v/v) ethanol fractionation. Sample
preparation and 2-DE analysis were performed as described in the Materials and Methods section. Proteins
(400 μg) were separated using linear IPG strips pH 4-7, followed by 15% SDS-PAGE and were detected by
colloidal CBB staining. Each gel shows healthy control; ethanol precipitate (A); ethanol supernatant (B); and
severe lung diseases patient; ethanol supernatant (C). Numbered spots indicate the MADI TOF MS/MS
analysed proteins as listed in Table 3.
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a chlorotriazine dye which has high affinity for albumin [14]. As a group, the immuno-
globulins represent the second most abundant proteins in the plasma or serum. It has
been reported that albumin depletion maya l s or e m o v es o m es m a l ll o wc o p yn u m b e r
proteins [15]. Therefore, in these experiments we used ethanol fractionation and found
that this simple and low cost experimental procedure can be used for removing immu-
noglobulins and part of the albumin. Moreover, using 50% (v/v) fractionation, we
showed that the ethanol supernatant contains all the protein spots that were found in
the ethanol precipitate and recovers more small MW proteins.
We have identified some proteins that could give a novel insight into the pathogen-
esis of mustard lung. One of the main findings was different isoforms of haptoglobin
in the plasma of severe lung disease patients but not in healthy controls. Haptoglobin
is present in normal human plasma at a concentration range of 0.3-1.9 mg/ml,
accounting for 0.4-2.6% of total plasma protein. Human haptoglobin is an inflamma-
tion-inducible plasma protein. It consists of 2 different types of a chains and a single
type of b chain connected by disulfide bridges (b-a-a-b) giving 3 major phenotypes
(Hp 1-1, Hp 2-1, Hp 2-2), the numbers 1 and 2 representing a1( 8 . 9k D a )a n da2( 1 6
kDa) chains, respectively. The b chain (40 kDa) is heavier than a chain and is identical
in all Hp types [16-19].
Our results (Figures 2B and 2C) show that under our experimental conditions, the
a2 chain (spots 11, 12, 13) is similarly expressed in the plasma of both experimental
Table 2 Comparison of spot volume and intensity in ethanol fractionated human
plasma
a
Spot# b Protein Ethanol Supernatant Ethanol Precipitate
Name % Volume % intensity % Volume % intensity
1 a2 HS glycoprotein 10 ± 1.4 23 ± 1.8** 8 ± 1.2 13 ± 1.6
2 a1-antitrypsin 160 ± 14 67 ± 6.4 170 ± 23 59 ± 4.7
3 Zinc a2 glycoprotein 36 ± 4.6** 46 ± 4.2** 12 ± 2.1 19 ± 4.8
4 SP40 20 ± 3.8 44 ± 2.7 21 ± 3.1 39 ± 3.2
5 Haptoglobin 36 ± 4.3** 51 ± 9.0** 19 ± 2.8 29 ± 2.5
6 Transthyretin 137 ± 19** 68 ± 5.6** 54 ± 13 33 ± 11
7 Apolipoprotein AIV 120 ± 11** 64 ± 8.3** 35 ± 7.8 37 ± 5.2
8 Apolipoprotein A1 140 ± 12 70 ± 4.1 121 ± 13 54 ± 5.9
8 Apolipoprotein A1 640 ± 23** 74 ± 8.2 405 ± 15 63 ± 6.2
9 Apolipoprotein A1 41 ± 3.0 59 ± 6.9 54 ± 4.7 36 ± 4.1
10 Retinol BP 4 53 ± 12** 58 ± 5.8* 27 ± 7.5 42 ± 5.5
11 Haptoglobin hp2a 73 ± 5.6** 56 ± 4.3** 41 ± 6.1 36 ± 4.2
12 Haptoglobin hp2a 215 ± 9.2** 70 ± 4.8 170 ± 8.5 62 ± 6.8
13 Haptoglobin hp2a 155 ± 8.4** 64 ± 6.8 91 ± 9.2 57 ± 6.8
14 Transthyretin 77 ± 5.8 56 ± 6.8 87 ± 9.2 54 ± 6.8
15 Transthyretin 10 ± 5.6 7.5 ± 6.8 11 ± 9.2 8.2 ± 6.8
18 Apolipoprotein CIII 123 ± 8.4** 58 ± 6.8 ** 91 ± 9.2 27 ± 6.8
19 Apolipoprotein CIII 125 ± 8.4** 79 ± 3.4** 65 ± 7.8 25 ± 4.3
20 Apolipoprotein CII 35 ± 4.4** 24 ± 7.2** 11 ± 9.2 8.9 ± 6.8↑
Data are mean ± SEM of the % volume and intensity of protein spots on the 2D gels multiplied by 100. Significant
difference between the samples were calculated using the Student’s t-test and marked by * if p < 0.05, ** if p < 0.01.
a. Spot numbers correspond to those in Figures 2A and 2B
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ples but not in the healthy controls. In our recent study of BAL fluid proteomics pat-
terns in SM exposed patients we also found that haptoglobin isoforms were
significantly elevated in moderate and severe lung disease patients compared to mild
and healthy controls [13]. Acute-phase proteins are induced shortly after exposure to
triggering events such as inflammation, infection, and trauma, and are thought to be
part of a general defense-response in injured tissue. But, these patients have been
exposed to SM more than 20 years ago. It seems that an ongoing damage is occurring
in lung of these patients. A recent proteomic study has also shown that levels of hapto-
globin are elevated in BAL fluid in patients with mild asthma, and reported that hapto-
globin may play a role in the differentiation of fibroblast progenitor cells, suggesting a
Table 3 Analysis of tryptic digests with MALDI -TOF/TOF-MS (MS/MS)
Spot
a
No
Protein name Database
b
id
MW/pI
kDa
MS/MS
c MALDI/
MS
d
Score
e
value
Coverage
f
(%)
1 a2H S
glycoprotein
gi156523970 39.3/5.43 4/4 [57, 101, 88, 71] 7/9 294 26
2 a1-antitrypsin gi157831596 44.3/5.37 2/3 [58, 100] 9/13 301 47
3 Zinc a2
glycoprotein
gi4699583 31.6/5.70 4/7 [57, 36, 75, 58] 6/10 577 65
4 SP40 gi338305 36.7/5.74 4/4 [147, 65, 62] 7/12 170 43
5 Haptoglobin gi3337390 38.2/6.14 3/5 [46, 117, 70] 6/12 209 31
6 Transthyretin gi114318993 20.2/5.16 3/4 [102, 87, 32] 4/10 276 55
7 Apolipoprotein AIV gi11957960 45.2/5.28 3/5 [61, 29, 42] 9/14 253 35
8 Apolipoprotein A1 gi178775 28.9/5.45 4/4 [54, 74, 57, 65] 7/16 482 73
9 Apolipoprotein A1 gi178775 28.9/5.45 4/5 [73, 37, 71, 61] 7/16 584 79
10 Retinol BP 4 gi18088326 23.0/5.76 3/4 [64, 125, 155] 6/10 472 58
11* Haptoglobin hp2a gi223976 41.7/6.23 2/3 [79, 36] 4/5 155 20
12* Haptoglobin hp2a gi296653 41.5/6.25 3/4 [92, 90, 53] 4/9 379 23
13* Haptoglobin hp2a gi296653 41.5/6.25 3/5 [42, 43, 30] 5/13 220 28
14 Transthyretin gi4507725 15.9/5.52 3/4 [118, 175, 28] 5/10 476 73
15 Transthyretin gi4507725 15.9/5.52 2/3 [114, 27] 3/8 216 65
16 IG J chain gi114319027 19.6/5.24 3/4 [80, 43, 39] 4/4 199 25
17 IG J chain gi114319027 19.6/5.24 2/3 [39, 28] 6/10 226 29
18 Apolipoprotein CIII gi4557323 10.8/5.23 2/3 [105, 33] 3/3 181 34
19 Apolipoprotein CIII gi4557323 10.8/5.23 2/3 [142, 58] 2/3 225 34
20 Apolipoprotein CII gi4557323 11.2/5.42 2/3 [38, 24] 3/8 132 56
21* Haptoglobin hp1a gi3337390 38.2/6.14 2/4 [69, 27] 2/5 182 15
22* Haptoglobin hp1a gi3337390 38.2/5.28 2/2 [68, 59] 5/8 170 30
23* Haptoglobin hp1a gi337390 38.2/5.28 3/4 [63, 51, 53] 6/9 164 25
24 Serum Amyloid A1 gi40316910 13.5/6.28 3/5 [130, 110, 21] 4/7 129 63
25 Albumin fragment gi19626079 22.4/6.2 3/8 [82, 85,103] 3/3 231 27
26 Serum Amyloid A1 gi40316910 13.5/6.28 3/3 [170, 130, 47] 6/9 181 80
a) Spot No. related to the annotation in Figure 2B and 2C. Number of peaks is given as matched to the protein/total
number of SNAP algorithm selected peaks in the spectrum. Mass quality was assessed using transferrin and BSA as
quality control internal standards. Score/coverage for transferrin and BSA was 421/50 and 216/29 respectively.
b) NRDB1 (6655203 protein sequence)
c) The column refers to the results of the MALDI-MS/MS analysis to the number and Mowse scores (in brackets) of
assigned peptides.
d) The column refers to the results of the MALDI-MS PMF analysis of the number of assigned peptides to total number
of measured peptide masses picked with SNAP algorithm.
e) MASCOT score value indicates the quality of database search results.
f) Sequence coverage, refers to the observed sequence coverage of the assigned protein
*. Molecular weight (MW) and pI are theoretical and * indicates proteins present on the gel at a MW or pI different to
these values
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sely Nishioka et al. showed that the serum concentration of haptoglobin was decreased
during acute exacerbation in asthmatic children [21]. Haptoglobin isoforms and frag-
ments are also elevated in plasma of severe acute respiratory syndrome (SARS) patients
[22]. Haptoglobin plays a crucial role in defense against hemoglobin-induced oxidative
stress by a mechanism thought to involve its high-affinity binding with hemoglobin
and preventing iron release from hemoglobin. However, it has yet to be shown that
haptoglobin itself is an antioxidant molecule [23]. Arredouani et al. [24] further
described the role of haptoglobin affecting the immune system, showing that haptoglo-
bin directly affects T-cells and suppress T-helper-cells through down-regulation of
cytokine production.
We found that Amyloid A1 isoforms only detected in the plasma of severe lung dis-
eases patients but not in healthy controls (Figure 2B and 2C). Similar results were
reported for SARS patients [22]. Although serum Amyloid A1 is not as commonly
used in human medicine as C- reactive protein (CRP), it is more sensitive to acute
response than CRP [25,26]. Serum Amyloid A1 is an acute-phase protein that is
induced, like CRP, by inflammatory mediators, including IL-6, IL-1b,a n dT N F - a, that
rises in acute exacerbation of COPD [27]. Serum Amyloid A1 is secreted from the
liver as the predominant apolipoprotein associated with plasma high density lipopro-
tein. We postulate that in our SM exposed patients ongoing tissue damage and repair
(remodeling) is occurring which leads to an increase in acute phase reactant proteins
such as haptoglobin and Amyloid A1.
In conclusion, this study complements our previous BAL fluid proteome analysis of
patients exposed to SM gas which resulted in identification of number of differentially
expressed proteins. To our knowledge this is the first study of plasma fluid proteome
in SM exposed subjects. In this and our previous study the patterns of differentially
expressed proteins identified in SM exposed patients are somewhat different from
other lung diseases. It seems that SM exposed lung has an aberrant tissue remodeling
which results in abnormal tissue architecture.
Materials and Methods
Chemicals
All chemicals used in these studies were analytical grade or equivalent and were
obtained from Sigma (St. Louis, MO) unless otherwise noted. Milli Q water (18.2 MΩ)
was used throughout.
Table 4 Spot volume and intensity in ethanol supernatant of lung disease patients
a
Spot# b Protein Name % Volume % intensity
21 Haptoglobin hp1 a 33 ± 4.2 28 ± 5.2
22 Haptoglobin hp1 a 143 ± 7.6 78 ± 5.3
23 Haptoglobin hp1a 69 ± 6.7 62 ± 3.9
24 Serum Amyloid A1 28 ± 3.2 24 ± 4.3
25 Albumin fragment 31 ± 6.9 26 ± 6.4
26 Serum Amyloid A1 105 ± 9.3 69 ± 3.6
a. Spot numbers correspond to those in Figures 2C which were only present in all lung disease patients’ plasma but
none of the healthy controls.
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According to the American Thoracic Society (ATS) classification and based on our
spirometric and high resolution computed tomography (HRCT) findings, the patients
were classified as severe lung diseases condition. Patients group included 20 male sub-
jects. A group of 20 healthy age-matched male individuals was used as the control.
This study was approved by the ethics committee of the research center of Baqiyatallah
University of Medical Sciences, and informed consent was obtained from all patients
and healthy controls. All participants were free to leave the study at will. The partici-
pant patients were suffering from pulmonary disorders due to previous exposure to a
single high dose of SM gas during the Iran-Iraq conflict in 1987. Inclusion criteria
were as follows: documented exposure to SM and documented diagnosis of chronic
pulmonary disease due to mustard gas. Exclusion criteria for the patients and the con-
trol subjects were history of a chronic disease (tuberculosis, diabetes, hypertension,
heart disease, hepatic diseases, etc.), resection of one or more lobes of the lungs, pneu-
monia and/or acute bronchitis, cigarette smoking or substance abuse. None of the
patients or control subjects had a history of allergy or asthma. All patients and controls
were in a stable condition and none of the participants had been administrated corti-
costeroids during the two-month period immediately preceding the studies.
Sample collection
Fasting venous blood samples were collected in the morning (8-10 am). Blood samples
were drawn into tubes containing K2EDTA and then immediately centrifuged at 1300
× g and 4°C for 10 min according to HUPO plasma proteomics project recommenda-
tion [28]. Supernatant was removed to a new tube and one tablet of complete protease
inhibitor cocktail (Roche, Mannheim, and Germany) was added. Then, sample were
promptly frozen in aliquots and stored at -80°C until used.
Sample preparation
Plasma samples were thawed at room temperature and centrifuged at 10,000 × g for 10
min at 4°C. Then clear supernatants were transferred to new microfuge tubes for
further processing. Total protein in plasma fluid was determined by the bicinchoninic
acid (BCA) assay and employed bovine albumin as the standard (Pierce, Rockford, IL).
The concentrations of proteins in plasma and different fractions were determined
using a standard curve generated by the absorbance at 562 nm.
Following procedures for ethanol fractionation were applied. All steps were per-
formed at 4°C. Plasma samples were diluted 1:1 (v/v) with Milli Q water in a new
microfuge tube and equilibrated to 4°C by gentle mixing (continuously on a vortex
mixer at a low setting) for 10 min. In new separate microfuge tubes containing 500 μl
of diluted plasma samples, different volumes of cold ethanol were added and total
volume was adjusted to 1000 μl with Milli Q water. Samples were incubated for an
additional hour with gentle mixing on the vortex mixer and were centrifuged at 10,000
× g for 15 min at 4°C. Supernatants were removed to new tubes, pellets were briefly
re-centrifuged and any residual supernatant was removed and added to the previous
supernatant fraction. For electrophoresis, the supernatants were dialyzed against 50
Mm Tris-HCl (pH 7.4) overnight to remove ethanol.
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For one dimensional SDS-PAGE analysis the collected ethanol supernatants and pellets
were reconstituted in 50 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 0.1% (w/v) bromophe-
nol blue and 10% (v/v) glycerol. Proteins were separated by mini 1-DE (10% T resol-
ving gels with 4% stacking gels; 10 μg protein/lane). Gels were electrophoresed at 30 V
for 30 min and then at 50 mA per gel for 45 min, and stained using Vorum silver
staining procedure as described recently
[29]. For 2-DE analysis dialyzed ethanol supernatants and pellets were reconstituted
in buffer consisting of 7 M urea, 1 M thiourea, 20 mM Tris, pH 7.5, 4% (w/v) 3-[(cho-
lamidopropyl) dimethylamino]-1-propanesulfonate (CHAPS), and centrifuged at 10,000
× g at room temperature for 5 min. Supernatants were taken for 2-DE gel analysis.
Protein concentration in the recovered samples was determined using a modification
of the method as described by Bradford [30].
Two dimensional gels were analysed using 400 μg proteins per 24-cm linear IPG
strips pH 4-7 (Bio Rad) as described previously [13]. IPG strips were reduced and alky-
lated, and then proteins were separated in the second dimension on homogeneous 15%
polyacrylamide gels in an Ettan DALTsix electrophoresis unit (GE healthcare, Uppsala,
Sweden). IPG strips were placed on the top of polyacrylamide gels (1 × 200 × 260
mm) and sealed with a solution of 1% (w/v) agarose containing a trace of bromophenol
blue. Gels were run in a running buffer, containing 25 mM Tris, 192 mM glycine, and
0.1% (w/v) SDS at 2W/gel for 45 min, followed by 6W/gel at 20°C until the bromophe-
nol blue had migrated to the bottom of the gel. Gels were fixed overnight in acetic
acid, methanol, water, 10:45:45 (v/v) and stained with colloidal Coomassie brilliant
blue (CBB) G-250 as described previously [13].
Gel analysis and protein identification
Analysis of spot patterns was performed using ImageMaster 2D Platinum software
(version 6.0; GE Healthcare). CBB stained gels were scanned in transmission scan
mode using Bio-Rad GS-800 calibrated densitometer at a resolution of 600 dots per
square inch (dpi). The scanned gels were saved as TIF images for subsequent analysis.
Protein spots were detected automatically. Manual spot editing or deleting (of artifacts)
was performed when necessary. The spots intensity, volume, or saliency was adjusted
in the preview mode using Image master software. Furthermore spots on all gels were
visually carefully inspected for inappropriate matching, staining artifacts, or bad spot
detection and conserved for analysis. To measure the volume and intensity of protein
spots on CBB-stained gels the volume and intensity of each spot was divided by the
total volume or intensity of all spots of the same gel. Since this method of normaliza-
tion produces extremely small values, the result was multiplied by a scaling factor of
100, which produced spot percentage volumes or intensity. Only those spots that were
reproducibly and statistically significant (p < 0.05) in intensity or volume were used for
analysis.
For mass analysis the protein spots of interest were aseptically removed under a
laminar flow hood. Processing of gel plugs, trypsin digestion and MALDI TOF MS/MS
analysis using a Bruker Autoflex III MALDI TOF/TOF instrument (Alphalyse, Den-
mark) and database searching was performed as described previously [13]. The MS
and MS/MS spectra were combined and used for a database search using the Mascot
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lowing criteria: Database search program: NRDB1 (6655203 protein sequence), species
of origin Homo sapience, peptide ion mass tolerance 60 ppm,, MS/MS tolerance
0.2 Da, peptide cut-off of 25, and digestion by trypsin allowing for no more than one
missed cleavage. The accuracy of mass detection was MH+ of 0.01 assuming possibility
of modification of cysteine by acrylamide and oxidation of methionine. Proteins identi-
fication was based on a combination of the peptide mass fingerprint (PMF) with pep-
tide masses, and several MS/MS spectra of selected peptides in each MALDI MS
spectrum. The protein and protein isoforms shown on the identification list is based
purely on the human protein database accession that gives the highest Mascot score.
To the extent that the different sequence isoforms are represented in individual data-
base accession numbers, these have been considered in the database search. Other
modifications and isoforms are not considered in this analysis. The positive protein
identification was based on a probability-scoring algorithm (http://www.matrixscience.
com) and the 95% confidence level for positive identification was a score = 80
Statistical analysis
All data are representative of at least three independent experiments with twenty indi-
viduals in each group and are expressed as means ± standard error of the mean (SEM).
Comparisons between two groups were performed using unpaired Student’s t-test. The
criterion for statistical significance was p < 0.05 for all comparisons.
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spectrometry; MS/MS: tandem mass spectrometry; PMF: peptide mass fingerprint; SARS: severe acute respiratory
syndrome; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; SM: sulfur mustard.
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